Genomewide association studies: history, rationale, and prospects for psychiatric disorders - PubMed (original) (raw)
Review
. 2009 May;166(5):540-56.
doi: 10.1176/appi.ajp.2008.08091354. Epub 2009 Apr 1.
Sven Cichon, Nick Craddock, Mark Daly, Stephen V Faraone, Pablo V Gejman, John Kelsoe, Thomas Lehner, Douglas F Levinson, Audra Moran, Pamela Sklar, Patrick F Sullivan
Collaborators
- PMID: 19339359
- PMCID: PMC3894622
- DOI: 10.1176/appi.ajp.2008.08091354
Review
Genomewide association studies: history, rationale, and prospects for psychiatric disorders
Psychiatric GWAS Consortium Coordinating Committee et al. Am J Psychiatry. 2009 May.
Abstract
Objective: The authors conducted a review of the history and empirical basis of genomewide association studies (GWAS), the rationale for GWAS of psychiatric disorders, results to date, limitations, and plans for GWAS meta-analyses.
Method: A literature review was carried out, power and other issues discussed, and planned studies assessed.
Results: Most of the genomic DNA sequence differences between any two people are common (frequency >5%) single nucleotide polymorphisms (SNPs). Because of localized patterns of correlation (linkage disequilibrium), 500,000 to 1,000,000 of these SNPs can test the hypothesis that one or more common variants explain part of the genetic risk for a disease. GWAS technologies can also detect some of the copy number variants (deletions and duplications) in the genome. Systematic study of rare variants will require large-scale resequencing analyses. GWAS methods have detected a remarkable number of robust genetic associations for dozens of common diseases and traits, leading to new pathophysiological hypotheses, although only small proportions of genetic variance have been explained thus far and therapeutic applications will require substantial further effort. Study design issues, power, and limitations are discussed. For psychiatric disorders, there are initial significant findings for common SNPs and for rare copy number variants, and many other studies are in progress.
Conclusions: GWAS of large samples have detected associations of common SNPs and of rare copy number variants with psychiatric disorders. More findings are likely, since larger GWAS samples detect larger numbers of common susceptibility variants, with smaller effects. The Psychiatric GWAS Consortium is conducting GWAS meta-analyses for schizophrenia, bipolar disorder, major depressive disorder, autism, and attention deficit hyperactivity disorder. Based on results for other diseases, larger samples will be required. The contribution of GWAS will depend on the true genetic architecture of each disorder.
Figures
Figure 1. Relationship among power, GRR (multiplicative inheritance) and sample size
The graphs show expected power (91) for a disease with 1% population prevalence (p - 5 × 10−8), depending on minor (less frequent) allele frequency of the tested SNP, sample size (assuming the N of cases shown in the graph legend, and the same N of controls (power is similar for the same N of case-parent trios), and_genotypic relative risk (GRR_), which is the ratio of the risk of disease to carriers of a particular genotype vs. non-carriers (thus, if GRR is 1.2, risk is increased by 20%). The calculations assume indirect association between a tested SNP allele and a risk allele at a correlation (r2) of 0.8, so that the effective sample sizes are approximately 80% of those shown. A sample of 8,000 cases and 8,000 controls will miss most associated alleles that confer much less than a 20% increase in risk (GRR << 1.2), whereas 20,000/20,000 would detect most associated alleles with GRR = 1.12 and frequency > 15-20%. Factors that affect power include:
- GRR. Power increases with GRR.
- Allele frequency and LD. Power increases with the minor allele frequency of the associated SNP and with stronger LD between than SNP and an untested risk allele.
- Mode of transmission. Power is greater for dominant and multiplicative (log additive) genetic effects, and less for recessive effects (particularly for rare alleles).
- Selection of controls. For diseases with higher prevalence (e.g., >> 5%), power increases if controls with the disorder/trait of interest are excluded.(40)
- Technical artifacts of all kinds can reduce power.
Similar articles
- Design considerations for genetic linkage and association studies.
Nsengimana J, Bishop DT. Nsengimana J, et al. Methods Mol Biol. 2012;850:237-62. doi: 10.1007/978-1-61779-555-8_13. Methods Mol Biol. 2012. PMID: 22307702 - A decade in psychiatric GWAS research.
Horwitz T, Lam K, Chen Y, Xia Y, Liu C. Horwitz T, et al. Mol Psychiatry. 2019 Mar;24(3):378-389. doi: 10.1038/s41380-018-0055-z. Epub 2018 Jun 25. Mol Psychiatry. 2019. PMID: 29942042 Free PMC article. Review. - Molecular genetic studies of complex phenotypes.
Marian AJ. Marian AJ. Transl Res. 2012 Feb;159(2):64-79. doi: 10.1016/j.trsl.2011.08.001. Epub 2011 Aug 31. Transl Res. 2012. PMID: 22243791 Free PMC article. Review. - Comprehensive cross-disorder analyses of CNTNAP2 suggest it is unlikely to be a primary risk gene for psychiatric disorders.
Toma C, Pierce KD, Shaw AD, Heath A, Mitchell PB, Schofield PR, Fullerton JM. Toma C, et al. PLoS Genet. 2018 Dec 26;14(12):e1007535. doi: 10.1371/journal.pgen.1007535. eCollection 2018 Dec. PLoS Genet. 2018. PMID: 30586385 Free PMC article.
Cited by
- Sex-specific and opposed effects of FKBP51 in glutamatergic and GABAergic neurons: Implications for stress susceptibility and resilience.
van Doeselaar L, Stark T, Mitra S, Yang H, Bordes J, Stolwijk L, Engelhardt C, Kovarova V, Narayan S, Brix LM, Springer M, Deussing JM, Lopez JP, Czisch M, Schmidt MV. van Doeselaar L, et al. Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2300722120. doi: 10.1073/pnas.2300722120. Epub 2023 May 30. Proc Natl Acad Sci U S A. 2023. PMID: 37252963 Free PMC article. - In vitro modeling of the neurobiological effects of glucocorticoids: A review.
Bassil K, Krontira AC, Leroy T, Escoto AIH, Snijders C, Pernia CD, Pasterkamp RJ, de Nijs L, van den Hove D, Kenis G, Boks MP, Vadodaria K, Daskalakis NP, Binder EB, Rutten BPF. Bassil K, et al. Neurobiol Stress. 2023 Feb 23;23:100530. doi: 10.1016/j.ynstr.2023.100530. eCollection 2023 Mar. Neurobiol Stress. 2023. PMID: 36891528 Free PMC article. Review. - Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models.
Sebastian R, Song Y, Pak C. Sebastian R, et al. Schizophr Res. 2022 Jul 11:S0920-9964(22)00263-8. doi: 10.1016/j.schres.2022.06.028. Online ahead of print. Schizophr Res. 2022. PMID: 35835709 Free PMC article. - Endosomal trafficking in schizophrenia.
Plooster M, Brennwald P, Gupton SL. Plooster M, et al. Curr Opin Neurobiol. 2022 Jun;74:102539. doi: 10.1016/j.conb.2022.102539. Epub 2022 Apr 8. Curr Opin Neurobiol. 2022. PMID: 35405628 Free PMC article. Review. - Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.
Lin P, Sun J, Lou X, Li D, Shi Y, Li Z, Ma P, Li P, Chen S, Jin W, Liu S, Chen Q, Gao Q, Zhu L, Xu J, Zhu M, Wang M, Liang K, Zhao L, Xu H, Dong K, Li Q, Cheng X, Chen J, Guo X. Lin P, et al. Gen Psychiatr. 2022 Feb 23;35(1):e100685. doi: 10.1136/gpsych-2021-100685. eCollection 2022. Gen Psychiatr. 2022. PMID: 35309241 Free PMC article.
References
- Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827–34. - PubMed
- Levinson DF. Meta-analysis in Psychiatric Genetics. Curr. Psychiatry Rep. 2005;7(2):143–151. - PubMed
Publication types
MeSH terms
Grants and funding
- G0801418/MRC_/Medical Research Council/United Kingdom
- U01 MH094411/MH/NIMH NIH HHS/United States
- R01 MH062276/MH/NIMH NIH HHS/United States
- U01 MH079470/MH/NIMH NIH HHS/United States
- MH-085520/MH/NIMH NIH HHS/United States
- U01 MH085520/MH/NIMH NIH HHS/United States
- R01 MH061686/MH/NIMH NIH HHS/United States
- R01 MH083094/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical